Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Br. J. Dermatol.

Title: The British journal of dermatology

Publisher: Wiley-Blackwell

ISSN (Electronic): 1365-2133

ISSN (Print): 0007-0963

Publication date (Electronic): Nov 2016

Volume: 175

Issue: 5

Affiliations

[1 ] Innovaderm Research, Montreal, QC, Canada.

[2 ] K Papp Clinical Research and Probity Medical Research Inc., Waterloo, ON, Canada.

[3 ] Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec, QC, Canada.

[4 ] SKiN Centre for Dermatology and Probity Medical Research Inc., Peterborough, ON, Canada.

[5 ] The Centre for Dermatology and Probity Medical Research Inc., Richmond Hill, ON, Canada.

[6 ] Pfizer Inc., Collegeville, PA, U.S.A.

[7 ] Pfizer Inc., Groton, CT, U.S.A.

[8 ] Pfizer Inc., Groton, CT, U.S.A. william.c.ports@pfizer.com.

Article

DOI: 10.1111/bjd.14871

PubMed ID: 27423107

SO-VID: 342536a7-9548-4d6f-a852-9d59baad64ae

History

Data availability:

Comments

Comment on this article

scite_

Cited by 123

See all cited by